NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Assessing the effectiveness and level of satisfaction of the Diflucan partnership program in Swaziland.

Lee S, Lauver H, Ali A, Lissfelt J, Sebati K, Ruxin J; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. E12843.

Columbia University School of International and Public Affairs, New York, United States

Issue: Since March 2002 the Diflucan Partnership Programme in Swaziland, a collaborative partnership between Pfizer Inc. and the Swaziland Ministry of Health, has provided 8,050 prescriptions of Diflucan (fluconazole) free-of-charge to patients suffering from two opportunistic infections attributed to HIV/AIDS, oesophageal candidiasis and cryptococcal candidiasis. As a critical component of this programme, approximately 95 medical practitioners and officials from the Ministry of Health and Social Welfare have been trained on the diagnosis and treatment of these two opportunistic infections. Description: In November 2003 Pfizer Inc. and Columbia University began a monitoring and evaluation study to assess the effectiveness and level of satisfaction obtained from the Diflucan Partnership Programme in Swaziland, Africa. The study obtains quantitative and qualitative responses from the Swaziland Ministry of Health and Social Welfare and from the Swaziland medical community involved in the Diflucan Partnership Programme. The research assesses the extent to which the programme: maximizes its reach in providing Diflucan free-of-charge to oesophageal candidiasis and cryptococcal meningitis patients with the greatest economic need; meets the training and technical needs of the medical staff in addressing these indications; enhances training and health education on both the professional and patient level; and provides for response feedback. Recommendations: Results of the study will provide Pfizer Inc. with important feedback on the Diflucan Partnership Programme to guide its future programme and partnership efforts, as well as provide important insights to governments and companies interested in drug partnerships.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Africa
  • Candidiasis
  • Candidiasis, Oral
  • Cooperative Behavior
  • Curriculum
  • Fluconazole
  • HIV Infections
  • Health Education
  • Humans
  • Meningitis, Cryptococcal
  • Organizations
  • Swaziland
  • education
Other ID:
  • GWAIDS0034963
UI: 102279179

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov